The Experts below are selected from a list of 35127 Experts worldwide ranked by ideXlab platform

Tomoo Kosuge - One of the best experts on this subject based on the ideXlab platform.

  • Administration of Pancrelipase as Effective Treatment for Hepatic Steatosis After Pancreatectomy.
    Pancreas, 2015
    Co-Authors: Yoji Kishi, Minoru Esaki, Kazuaki Shimada, Satoshi Nara, Tomoo Kosuge
    Abstract:

    To evaluate the incidence of Hepatic Steatosis after pancreatectomy and whether pancrelipase improves Steatosis more effectively than other conventional digestive enzymes. Patients who underwent distal pancreatectomy, pancreaticoduodenectomy (PD), or total pancreatectomy (TP) from August 2008 to July 2013 were included. Incidence of newly developed Hepatic Steatosis recognized by computed tomography and outcomes by treatment with pancrealipase or other enzymes were evaluated. A total of 473 patients were evaluated. Among 366 patients who did not take any digestive enzymes until the recognition of Steatosis or the last follow-up date, Hepatic Steatosis was recognized in 3% (4/130), 17% (38/229), and 45% (3/7) of patients after distal pancreatectomy, PD, and TP, respectively, during the median follow-up of 641 days. Seventy patients including 25 patients taking digestive enzymes showed Hepatic Steatosis and were treated with pancrelipase (20 patients), other enzymes (19 patients), or no enzyme (31 patients). Cumulative improvement rate after 1 year of treatment in the 3 groups was 92%, 51%, and 56%, respectively, and that of the pancrelipase group was significantly better than the other 2 groups. The risk of Hepatic Steatosis should be a concern after PD and TP. Treatment with pancrelipase was more effective compared to other enzymes.

  • Administration of Pancrelipase as Effective Treatment for Hepatic Steatosis After Pancreatectomy.
    Pancreas, 2015
    Co-Authors: Yoji Kishi, Minoru Esaki, Kazuaki Shimada, Satoshi Nara, Tomoo Kosuge
    Abstract:

    OBJECTIVES To evaluate the incidence of Hepatic Steatosis after pancreatectomy and whether pancrelipase improves Steatosis more effectively than other conventional digestive enzymes. METHODS Patients who underwent distal pancreatectomy, pancreaticoduodenectomy (PD), or total pancreatectomy (TP) from August 2008 to July 2013 were included. Incidence of newly developed Hepatic Steatosis recognized by computed tomography and outcomes by treatment with pancrealipase or other enzymes were evaluated. RESULTS A total of 473 patients were evaluated. Among 366 patients who did not take any digestive enzymes until the recognition of Steatosis or the last follow-up date, Hepatic Steatosis was recognized in 3% (4/130), 17% (38/229), and 45% (3/7) of patients after distal pancreatectomy, PD, and TP, respectively, during the median follow-up of 641 days. Seventy patients including 25 patients taking digestive enzymes showed Hepatic Steatosis and were treated with pancrelipase (20 patients), other enzymes (19 patients), or no enzyme (31 patients). Cumulative improvement rate after 1 year of treatment in the 3 groups was 92%, 51%, and 56%, respectively, and that of the pancrelipase group was significantly better than the other 2 groups. CONCLUSION The risk of Hepatic Steatosis should be a concern after PD and TP. Treatment with pancrelipase was more effective compared to other enzymes.

Yoji Kishi - One of the best experts on this subject based on the ideXlab platform.

  • Administration of Pancrelipase as Effective Treatment for Hepatic Steatosis After Pancreatectomy.
    Pancreas, 2015
    Co-Authors: Yoji Kishi, Minoru Esaki, Kazuaki Shimada, Satoshi Nara, Tomoo Kosuge
    Abstract:

    To evaluate the incidence of Hepatic Steatosis after pancreatectomy and whether pancrelipase improves Steatosis more effectively than other conventional digestive enzymes. Patients who underwent distal pancreatectomy, pancreaticoduodenectomy (PD), or total pancreatectomy (TP) from August 2008 to July 2013 were included. Incidence of newly developed Hepatic Steatosis recognized by computed tomography and outcomes by treatment with pancrealipase or other enzymes were evaluated. A total of 473 patients were evaluated. Among 366 patients who did not take any digestive enzymes until the recognition of Steatosis or the last follow-up date, Hepatic Steatosis was recognized in 3% (4/130), 17% (38/229), and 45% (3/7) of patients after distal pancreatectomy, PD, and TP, respectively, during the median follow-up of 641 days. Seventy patients including 25 patients taking digestive enzymes showed Hepatic Steatosis and were treated with pancrelipase (20 patients), other enzymes (19 patients), or no enzyme (31 patients). Cumulative improvement rate after 1 year of treatment in the 3 groups was 92%, 51%, and 56%, respectively, and that of the pancrelipase group was significantly better than the other 2 groups. The risk of Hepatic Steatosis should be a concern after PD and TP. Treatment with pancrelipase was more effective compared to other enzymes.

  • Administration of Pancrelipase as Effective Treatment for Hepatic Steatosis After Pancreatectomy.
    Pancreas, 2015
    Co-Authors: Yoji Kishi, Minoru Esaki, Kazuaki Shimada, Satoshi Nara, Tomoo Kosuge
    Abstract:

    OBJECTIVES To evaluate the incidence of Hepatic Steatosis after pancreatectomy and whether pancrelipase improves Steatosis more effectively than other conventional digestive enzymes. METHODS Patients who underwent distal pancreatectomy, pancreaticoduodenectomy (PD), or total pancreatectomy (TP) from August 2008 to July 2013 were included. Incidence of newly developed Hepatic Steatosis recognized by computed tomography and outcomes by treatment with pancrealipase or other enzymes were evaluated. RESULTS A total of 473 patients were evaluated. Among 366 patients who did not take any digestive enzymes until the recognition of Steatosis or the last follow-up date, Hepatic Steatosis was recognized in 3% (4/130), 17% (38/229), and 45% (3/7) of patients after distal pancreatectomy, PD, and TP, respectively, during the median follow-up of 641 days. Seventy patients including 25 patients taking digestive enzymes showed Hepatic Steatosis and were treated with pancrelipase (20 patients), other enzymes (19 patients), or no enzyme (31 patients). Cumulative improvement rate after 1 year of treatment in the 3 groups was 92%, 51%, and 56%, respectively, and that of the pancrelipase group was significantly better than the other 2 groups. CONCLUSION The risk of Hepatic Steatosis should be a concern after PD and TP. Treatment with pancrelipase was more effective compared to other enzymes.

Helen H Hobbs - One of the best experts on this subject based on the ideXlab platform.

  • prevalence of Hepatic Steatosis in an urban population in the united states impact of ethnicity
    Hepatology, 2004
    Co-Authors: Jeffrey D Browning, Lidia S Szczepaniak, Robert L Dobbins, Pamela Nuremberg, Jonathan Cohen, Jay D. Horton, Scott M. Grundy, Helen H Hobbs
    Abstract:

    Despite the increasing prevalence of nonalcoholic fatty liver disease (NAFLD), its pathogenesis and clinical significance remain poorly defined. In this study, we examined and compared the distribution of Hepatic triglyceride content (HTGC) in 2,287 subjects from a multiethnic, population-based sample (32.1% white, 48.3% black, and 17.5% Hispanic) using proton magnetic resonance spectroscopy. HTGC varied over a wide range (0.0%-41.7%; median, 3.6%) in the population. Almost one third of the population had Hepatic Steatosis, and most subjects with Hepatic Steatosis had normal levels of serum alanine aminotransferase (79%). The frequency of Hepatic Steatosis varied significantly with ethnicity (45% in Hispanics; 33% in whites; 24% in blacks) and sex (42% in white men; 24% in white women). The higher prevalence of Hepatic Steatosis in Hispanics was due to the higher prevalence of obesity and insulin resistance in this ethnic group. However, the lower frequency of Hepatic Steatosis in blacks was not explained by ethnic differences in body mass index, insulin resistance, ethanol ingestion, or medication use. The prevalence of Hepatic Steatosis was greater in men than women among whites, but not in blacks or Hispanics. The ethnic differences in the frequency of Hepatic Steatosis in this study mirror those observed previously for NAFLD-related cirrhosis (Hispanics > whites > blacks). In conclusion, the significant ethnic and sex differences in the prevalence of Hepatic Steatosis documented in this study may have a profound impact on susceptibility to Steatosis-related liver disease. (HEPATOLOGY 2004;40:1387–1395.)

  • prevalence of Hepatic Steatosis in an urban population in the united states impact of ethnicity
    Hepatology, 2004
    Co-Authors: Jeffrey D Owning, Lidia S Szczepaniak, Robert L Dobbins, Pamela Nuremberg, Jay D Horto, Jonatha Cohe, Scott M. Grundy, Helen H Hobbs
    Abstract:

    Despite the increasing prevalence of nonalcoholic fatty liver disease (NAFLD), its pathogenesis and clinical significance remain poorly defined. In this study, we examined and compared the distribution of Hepatic triglyceride content (HTGC) in 2,287 subjects from a multiethnic, population-based sample (32.1% white, 48.3% black, and 17.5% Hispanic) using proton magnetic resonance spectroscopy. HTGC varied over a wide range (0.0%-41.7%; median, 3.6%) in the population. Almost one third of the population had Hepatic Steatosis, and most subjects with Hepatic Steatosis had normal levels of serum alanine aminotransferase (79%). The frequency of Hepatic Steatosis varied significantly with ethnicity (45% in Hispanics; 33% in whites; 24% in blacks) and sex (42% in white men; 24% in white women). The higher prevalence of Hepatic Steatosis in Hispanics was due to the higher prevalence of obesity and insulin resistance in this ethnic group. However, the lower frequency of Hepatic Steatosis in blacks was not explained by ethnic differences in body mass index, insulin resistance, ethanol ingestion, or medication use. The prevalence of Hepatic Steatosis was greater in men than women among whites, but not in blacks or Hispanics. The ethnic differences in the frequency of Hepatic Steatosis in this study mirror those observed previously for NAFLD-related cirrhosis (Hispanics > whites > blacks). In conclusion, the significant ethnic and sex differences in the prevalence of Hepatic Steatosis documented in this study may have a profound impact on susceptibility to Steatosis-related liver disease.

Kazuaki Shimada - One of the best experts on this subject based on the ideXlab platform.

  • Administration of Pancrelipase as Effective Treatment for Hepatic Steatosis After Pancreatectomy.
    Pancreas, 2015
    Co-Authors: Yoji Kishi, Minoru Esaki, Kazuaki Shimada, Satoshi Nara, Tomoo Kosuge
    Abstract:

    To evaluate the incidence of Hepatic Steatosis after pancreatectomy and whether pancrelipase improves Steatosis more effectively than other conventional digestive enzymes. Patients who underwent distal pancreatectomy, pancreaticoduodenectomy (PD), or total pancreatectomy (TP) from August 2008 to July 2013 were included. Incidence of newly developed Hepatic Steatosis recognized by computed tomography and outcomes by treatment with pancrealipase or other enzymes were evaluated. A total of 473 patients were evaluated. Among 366 patients who did not take any digestive enzymes until the recognition of Steatosis or the last follow-up date, Hepatic Steatosis was recognized in 3% (4/130), 17% (38/229), and 45% (3/7) of patients after distal pancreatectomy, PD, and TP, respectively, during the median follow-up of 641 days. Seventy patients including 25 patients taking digestive enzymes showed Hepatic Steatosis and were treated with pancrelipase (20 patients), other enzymes (19 patients), or no enzyme (31 patients). Cumulative improvement rate after 1 year of treatment in the 3 groups was 92%, 51%, and 56%, respectively, and that of the pancrelipase group was significantly better than the other 2 groups. The risk of Hepatic Steatosis should be a concern after PD and TP. Treatment with pancrelipase was more effective compared to other enzymes.

  • Administration of Pancrelipase as Effective Treatment for Hepatic Steatosis After Pancreatectomy.
    Pancreas, 2015
    Co-Authors: Yoji Kishi, Minoru Esaki, Kazuaki Shimada, Satoshi Nara, Tomoo Kosuge
    Abstract:

    OBJECTIVES To evaluate the incidence of Hepatic Steatosis after pancreatectomy and whether pancrelipase improves Steatosis more effectively than other conventional digestive enzymes. METHODS Patients who underwent distal pancreatectomy, pancreaticoduodenectomy (PD), or total pancreatectomy (TP) from August 2008 to July 2013 were included. Incidence of newly developed Hepatic Steatosis recognized by computed tomography and outcomes by treatment with pancrealipase or other enzymes were evaluated. RESULTS A total of 473 patients were evaluated. Among 366 patients who did not take any digestive enzymes until the recognition of Steatosis or the last follow-up date, Hepatic Steatosis was recognized in 3% (4/130), 17% (38/229), and 45% (3/7) of patients after distal pancreatectomy, PD, and TP, respectively, during the median follow-up of 641 days. Seventy patients including 25 patients taking digestive enzymes showed Hepatic Steatosis and were treated with pancrelipase (20 patients), other enzymes (19 patients), or no enzyme (31 patients). Cumulative improvement rate after 1 year of treatment in the 3 groups was 92%, 51%, and 56%, respectively, and that of the pancrelipase group was significantly better than the other 2 groups. CONCLUSION The risk of Hepatic Steatosis should be a concern after PD and TP. Treatment with pancrelipase was more effective compared to other enzymes.

Minoru Esaki - One of the best experts on this subject based on the ideXlab platform.

  • Administration of Pancrelipase as Effective Treatment for Hepatic Steatosis After Pancreatectomy.
    Pancreas, 2015
    Co-Authors: Yoji Kishi, Minoru Esaki, Kazuaki Shimada, Satoshi Nara, Tomoo Kosuge
    Abstract:

    To evaluate the incidence of Hepatic Steatosis after pancreatectomy and whether pancrelipase improves Steatosis more effectively than other conventional digestive enzymes. Patients who underwent distal pancreatectomy, pancreaticoduodenectomy (PD), or total pancreatectomy (TP) from August 2008 to July 2013 were included. Incidence of newly developed Hepatic Steatosis recognized by computed tomography and outcomes by treatment with pancrealipase or other enzymes were evaluated. A total of 473 patients were evaluated. Among 366 patients who did not take any digestive enzymes until the recognition of Steatosis or the last follow-up date, Hepatic Steatosis was recognized in 3% (4/130), 17% (38/229), and 45% (3/7) of patients after distal pancreatectomy, PD, and TP, respectively, during the median follow-up of 641 days. Seventy patients including 25 patients taking digestive enzymes showed Hepatic Steatosis and were treated with pancrelipase (20 patients), other enzymes (19 patients), or no enzyme (31 patients). Cumulative improvement rate after 1 year of treatment in the 3 groups was 92%, 51%, and 56%, respectively, and that of the pancrelipase group was significantly better than the other 2 groups. The risk of Hepatic Steatosis should be a concern after PD and TP. Treatment with pancrelipase was more effective compared to other enzymes.

  • Administration of Pancrelipase as Effective Treatment for Hepatic Steatosis After Pancreatectomy.
    Pancreas, 2015
    Co-Authors: Yoji Kishi, Minoru Esaki, Kazuaki Shimada, Satoshi Nara, Tomoo Kosuge
    Abstract:

    OBJECTIVES To evaluate the incidence of Hepatic Steatosis after pancreatectomy and whether pancrelipase improves Steatosis more effectively than other conventional digestive enzymes. METHODS Patients who underwent distal pancreatectomy, pancreaticoduodenectomy (PD), or total pancreatectomy (TP) from August 2008 to July 2013 were included. Incidence of newly developed Hepatic Steatosis recognized by computed tomography and outcomes by treatment with pancrealipase or other enzymes were evaluated. RESULTS A total of 473 patients were evaluated. Among 366 patients who did not take any digestive enzymes until the recognition of Steatosis or the last follow-up date, Hepatic Steatosis was recognized in 3% (4/130), 17% (38/229), and 45% (3/7) of patients after distal pancreatectomy, PD, and TP, respectively, during the median follow-up of 641 days. Seventy patients including 25 patients taking digestive enzymes showed Hepatic Steatosis and were treated with pancrelipase (20 patients), other enzymes (19 patients), or no enzyme (31 patients). Cumulative improvement rate after 1 year of treatment in the 3 groups was 92%, 51%, and 56%, respectively, and that of the pancrelipase group was significantly better than the other 2 groups. CONCLUSION The risk of Hepatic Steatosis should be a concern after PD and TP. Treatment with pancrelipase was more effective compared to other enzymes.